"Oxazolidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.
| Descriptor ID |
D023303
|
| MeSH Number(s) |
D03.383.129.462.600
|
| Concept/Terms |
Oxazolidin-2-one- Oxazolidin-2-one
- Oxazolidin 2 one
- 2-oxazolidinone
- 2 oxazolidinone
- 2-Oxazolidone
- 2 Oxazolidone
- 1,3-Oxazolidin-2-one
- 1,3 Oxazolidin 2 one
- 1,3-Oxazolidine-2-one
- 1,3 Oxazolidine 2 one
|
Below are MeSH descriptors whose meaning is more general than "Oxazolidinones".
Below are MeSH descriptors whose meaning is more specific than "Oxazolidinones".
This graph shows the total number of publications written about "Oxazolidinones" by people in this website by year, and whether "Oxazolidinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oxazolidinones" by people in Profiles.
-
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trials. Pharmacol Res Perspect. 2024 Dec; 12(6):e70010.
-
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol. 2015 Jan-Feb; 9(1):65-71.
-
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014 Jan 01; 113(1):76-83.
-
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res. 2013 Feb; 54(2):467-72.
-
Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15.
-
Aqueous and vitreous penetration of linezolid and levofloxacin after oral administration. J Ocul Pharmacol Ther. 2010 Dec; 26(6):579-86.
-
Update on CETP inhibition. J Clin Lipidol. 2010 Sep-Oct; 4(5):394-8.
-
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009 Oct; 158(4):513-519.e3.
-
Raf Kinase Inhibitory Protein protects cells against locostatin-mediated inhibition of migration. PLoS One. 2009 Jun 24; 4(6):e6028.
-
6-O-Benzyl- and 6-O-silyl-N-acetyl-2-amino-2-N,3-O-carbonyl-2-deoxyglucosides: effective glycosyl acceptors in the glucosamine 4-OH Series. effect of anomeric stereochemistry on the removal of the oxazolidinone group. J Org Chem. 2005 Feb 18; 70(4):1291-6.